Skip to main content

AAN.com

Articles

December 30, 2009

Alzheimer's Disease Neuroimaging Initiative (ADNI)
Clinical characterization

R. C. Petersen, PhD, MD, P. S. Aisen, MD, L. A. Beckett, PhD, M. C. Donohue, PhD, A. C. Gamst, PhD, D. J. Harvey, PhD, C. R. Jack, Jr, MD, W. J. Jagust, MD, L. M. Shaw, PhD, A. W. Toga, PhD, J. Q. Trojanowski, MD, PhD, and M. W. Weiner, MDAuthors Info & Affiliations

January 19, 2010 issue

74 (3) 201-209

https://doi.org/10.1212/WNL.0b013e3181cb3e25

Abstract

Background: Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally.

Objective: To characterize cross-sectionally and longitudinally clinical measures in normal controls, subjects with MCI, and subjects with mild Alzheimer disease (AD) to enable the assessment of the utility of neuroimaging and chemical biomarker measures.

Methods: A total of 819 subjects (229 cognitively normal, 398 with MCI, and 192 with AD) were enrolled at baseline and followed for 12 months using standard cognitive and functional measures typical of clinical trials.

Results: The subjects with MCI were more memory impaired than the cognitively normal subjects but not as impaired as the subjects with AD. Nonmemory cognitive measures were only minimally impaired in the subjects with MCI. The subjects with MCI progressed to dementia in 12 months at a rate of 16.5% per year. Approximately 50% of the subjects with MCI were on antidementia therapies. There was minimal movement on the Alzheimer's Disease Assessment Scale–Cognitive Subscale for the normal control subjects, slight movement for the subjects with MCI of 1.1, and a modest change for the subjects with AD of 4.3. Baseline CSF measures of Aβ-42 separated the 3 groups as expected and successfully predicted the 12-month change in cognitive measures.

Conclusion: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics. The 12-month progression rate of MCI was as predicted, and the CSF measures heralded progression of clinical measures over 12 months.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (appendix_e-1_co-investigators.doc)

Download
42.50 KB

File (petersen_74_201.pdf)

Download
1.49 MB

REFERENCES

1.

Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154–159.

2.

Petersen RC, Parisi JE, Dickson DW, et al. Neuropathology of amnestic mild cognitive impairment. Arch Neurol 2006;63:665–672.

3.

Jicha GA, Parisi JE, Dickson DW, et al. Neuropathological outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006;63:674–681.

4.

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–194.

5.

Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006;367:1262–1270.

6.

Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007;6:295–303.

7.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.

8.

Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397–1403.

9.

Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's Disease Neuroimaging Initiative. In: Pettrella JR, Doraiswamy PM, eds. Neuroimaging Clinics of North America: Alzheimer's Disease: 100 Years of Progress. Philadelphia: Elsevier Saunders; 2005:869–877.

10.

Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632–637.

11.

Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37–49.

12.

Wechsler DA. Wechsler Memory Scale–Revised. New York: Psychological Corporation; 1987.

13.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.

14.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944.

15.

Reitan R. Validity of the Trail-Making Test as an indication of organic brain damage. Percept Mot Skills 1958;8:271–276.

16.

Wechsler DA. Wechsler Adult Intelligence Scale–Revised. New York: Psychological Corporation; 1987.

17.

Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test, 2nd ed. Philadelphia: Lea & Febiger; 1982.

18.

Rey A. l'Examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964.

19.

Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.

20.

Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–1364.

21.

Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–974.

22.

Wellner JA, Zahn Y. A hybrid algorithm for computation of the nonparametric maximum likelihood estimator from censored data. J Am Stat Assoc 1997;92:945–959.

23.

SAS/STAT® version 9. Cary, NC: SAS Institute, Inc.; 2004.

24.

R Foundation for Statistical Computing/R Development Core Team. A Language and Environment for Statistical Computing. Vienna, Austria; 2006.

25.

Petersen RC, Thomas RG, Grundman M, et al. Donepezil and vitamin E in the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.

26.

Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007;6:501–512.

27.

Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204–1215.

28.

Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024–2035.

Information & Authors

Information

Published In

Neurology^®

Volume 74 • Number 3 • January 19, 2010

Pages: 201-209

PubMed: 20042704

Copyright

© 2010.

Publication History

Published online: December 30, 2009

Published in print: January 19, 2010

Permissions

Request permissions for this article.

Request Permissions

Notes

Authors

Affiliations & Disclosures

R. C. Petersen, PhD, MD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

P. S. Aisen, MD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

L. A. Beckett, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

M. C. Donohue, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

A. C. Gamst, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

D. J. Harvey, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

C. R. Jack, Jr, MD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

W. J. Jagust, MD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

L. M. Shaw, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

A. W. Toga, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

J. Q. Trojanowski, MD, PhD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

M. W. Weiner, MD

From the Departments of Neurology (R.C.P.) and Radiology (C.R.J.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (P.S.A.) and Division of Biostatistics, School of Medicine (L.A.B., D.J.H.), University of California, Davis; Department of Neurosciences and Biostatistics (M.C.D., A.C.G.), University of California, San Diego; Helen Willis Neuroscience Institute (W.J.J.), University of California, Berkley; Department of Laboratory Medicine (L.M.S., J.Q.T.), University of Pennsylvania School of Medicine, Philadelphia; Toga Laboratory of Neuroimaging (A.W.T.), Department of Neurology, UCLA School of Medicine, Los Angeles, CA; and Center for Imaging of Neurodegenerative Diseases (M.W.W.), University of California, San Francisco.

View all articles by this author

Notes

Address correspondence and reprint requests to Dr. Ronald C. Petersen, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By

- Aravind Lathika Rajendrakumar,
- Konstantin G. Arbeev,
- Olivia Bagley,
- Matt Duan,
- Anatoliy I. Yashin,
- Svetlana Ukraintseva,
APOE4 and infectious diseases jointly contribute to brain glucose hypometabolism, a biomarker of Alzheimer’s pathology: New findings from the ADNI, PLOS ONE, 20, 1, (e0316808), (2025).https://doi.org/10.1371/journal.pone.0316808
Crossref
- Eftychia Bellou,
- Woori Kim,
- Ganna Leonenko,
- Feifei Tao,
- Emily Simmonds,
- Ying Wu,
- Niklas Mattsson-Carlgren,
- Oskar Hansson,
- Michael W. Nagle,
- Valentina Escott-Price,
Benchmarking Alzheimer’s disease prediction: personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies, Alzheimer's Research & Therapy, 17, 1, (2025).https://doi.org/10.1186/s13195-024-01664-9
Crossref
- Carlos Platero,
Temporal modeling and AT profiles in the early phase of Alzheimer's disease, Journal of Alzheimer's Disease Reports, 9, (2025).https://doi.org/10.1177/25424823241306097
Crossref
- Jingru Wang,
- Asta Debora,
- Lixuan Chen,
- Haisong Chen,
- Xuemiao Zhao,
- Mengying Yu,
- Yunjun Yang,
Association of small vessel disease progression with longitudinal cognitive decline across mild cognitive impairment, Journal of Alzheimer’s Disease, (2025).https://doi.org/10.1177/13872877241305800
Crossref
- Jinwei Liu,
- Yashu Xu,
- Yi Liu,
- Huating Luo,
- Wenxiang Huang,
- Lizhong Yao,
Attention-Guided 3D CNN With Lesion Feature Selection for Early Alzheimer's Disease Prediction Using Longitudinal sMRI, IEEE Journal of Biomedical and Health Informatics, 29, 1, (324-332), (2025).https://doi.org/10.1109/JBHI.2024.3482001
Crossref
- Yuanwang Zhang,
- Kaicong Sun,
- Yuxiao Liu,
- Fang Xie,
- Qihao Guo,
- Dinggang Shen,
A Modality-Flexible Framework for Alzheimer's Disease Diagnosis Following Clinical Routine, IEEE Journal of Biomedical and Health Informatics, 29, 1, (535-546), (2025).https://doi.org/10.1109/JBHI.2024.3472011
Crossref
- Chunhua Zhang,
- Bingyu Li,
- Kok Pin Ng,
- Yaojun Tai,
- Yuanming Tai,
- Xicheng Song,
- Min Kong,
- Maowen Ba,
Plasma neurofilament light mediates the effects of Apolipoprotein E on brain atrophy and cognitive decline in the comorbid Alzheimer's disease and cerebral small vessel disease, The Journal of Prevention of Alzheimer's Disease, (100054), (2025).https://doi.org/10.1016/j.tjpad.2024.100054
Crossref
- Rocio Diaz Escarcega,
- Vijay Kumar M. J.,
- Vasilia E. Kyriakopoulos,
- Guadalupe J. Ortiz,
- Aaron M. Gusdon,
- Huihui Fan,
- Pedram Peesh,
- Maria P. Blasco Conesa,
- Gabriela Delevati Colpo,
- Hilda W. Ahnstedt,
- Lucy Couture,
- Stella H. Kim,
- Miriam Hinojosa,
- Christine M. Farrell,
- Sean P. Marrelli,
- Akihiko Urayama,
- Bhanu P. Ganesh,
- Paul E. Schulz,
- Louise D. McCullough,
- Andrey S. Tsvetkov,
Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism, Neurobiology of Disease, 204, (106747), (2025).https://doi.org/10.1016/j.nbd.2024.106747
Crossref
- Eun Woo Kim,
- Keun You Kim,
- Eosu Kim,
Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers, The Journal of nutrition, health and aging, 29, 2, (100444), (2025).https://doi.org/10.1016/j.jnha.2024.100444
Crossref
- Yilin Leng,
- Wenju Cui,
- Bai Chen,
- Xi Jiang,
- Yunsong Peng,
- Jian Zheng,
Adaptive critical subgraph mining for cognitive impairment conversion prediction with T1-MRI-based brain network, Expert Systems with Applications, 264, (125809), (2025).https://doi.org/10.1016/j.eswa.2024.125809
Crossref
See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
[email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

advertisement

Impact Factor

We are pleased to announce that Neurology^® was awarded a new Impact Factor of 8.4. Explore our latest research and articles and join our community of distinguished authors by submitting your work .

Open Review Pilot Project

Explore peer reviews, author responses, and editor comments on selected articles.

Learn More

Letters to the Editor

The Letters section represents an opportunity for ongoing author debate and post-publication peer review. View our submission guidelines for Letters to the Editor before submitting your comment.

Submit a Letter for this article

View full text|Download PDF